Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 5 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 2 |
| Pharmaceutical Pricing and Reimbursement Introduction | 10 | 1 |
| Pharmaceutical Pricing and Reimbursement Global Economic Issues | 11 | 6 |
| Trend in Global Pricing and Reimbursement Regime | 11 | 1 |
| Trend Analysis of Healthcare Expenditure Per Capita | 12 | 1 |
| Public Health Expenditure as a Percentage of Total Health Expenditure | 13 | 2 |
| Out-of-Pocket Health Expenditure as a Percentage of Private Expenditure on Health | 15 | 1 |
| Healthy Life Years beyond the Age of 65 | 16 | 1 |
| Pharmaceutical Pricing and Reimbursement Global Issues | 17 | 3 |
| Reference Prices | 17 | 1 |
| International Price Referencing Adopted to Contain Healthcare Expenditure | 17 | 1 |
| Pharmaceutical Price Capping to Encourage the Use of Generic Drugs | 17 | 1 |
| Positive and Negative Price Formulary to Provide More Clarity on Drugs Covered by Health Insurance | 17 | 1 |
| Value-Based Pricing Systems and Risk-Sharing Models Evaluate Drugs Based on Value and Not Cost | 18 | 1 |
| Single Pricing Strategy in the European Union is a Debatable Issue | 19 | 1 |
| Faster Pricing and Reimbursement Decisions Ensure Quicker Medicine Access and Return on Investments | 19 | 1 |
| Issues in Pricing and Reimbursement in Orphan Drugs | 19 | 1 |
| Difficulty in Economic Evaluation of Orphan Drugs | 19 | 1 |
| Pharmaceutical Pricing and Reimbursement Pricing and Reimbursement by Geography | 20 | 5 |
| The US | 20 | 1 |
| Macroeconomic Factors (PEST Analysis) | 20 | 1 |
| Healthcare System in the Country | 20 | 1 |
| Healthcare Expenditure as a Percentage of GDP | 21 | 1 |
| Private and Government Expenditure on Healthcare as a Percentage of Total Healthcare Expenditure | 22 | 1 |
| Drug Pricing and Reimbursement Authorities | 23 | 1 |
| Issues in Pricing and Reimbursement | 23 | 1 |
| Manufacturers of Branded Drugs Increase Price before Patent Expiry to Fund R&D | 23 | 1 |
| Retail Sector has been Witnessing a Generic Price War | 23 | 1 |
| Unnecessary Healthcare Expenditure Resulted in a Loss of $800 $900 Billion in 2011 | 24 | 1 |
| Donut Hole to Affect Patient Healthcare Spending until 2020 | 24 | 1 |
| Proposal to Save Expenditures by Designing Innovative Policies | 24 | 1 |
| Medicare Part B Drug Pricing Does Not Reflect Market Price Accurately | 24 | 1 |
| Top Five Countries of Europe | 25 | 26 |
| Proposal to Speed Up Pricing and Reimbursement Decisions in Europe | 25 | 1 |
| The UK | 25 | 1 |
| Macroeconomic Factors (PEST Analysis) | 25 | 1 |
| Healthcare System in the Country | 26 | 1 |
| NHS Authorities and Trusts | 26 | 1 |
| Healthcare Expenditure as a Percentage of GDP | 27 | 1 |
| Private and Government Expenditure on Healthcare as a Percentage of Total Healthcare Expenditure | 28 | 1 |
| Drug Pricing and Reimbursement Authorities | 29 | 1 |
| Trends in Pricing and Reimbursement | 29 | 1 |
| New Recommendations in 2009 for the Pharmaceutical Pricing and Regulation Scheme | 29 | 2 |
| Value-Based Pricing to Replace the Pharmaceutical Price Regulation Scheme | 31 | 1 |
| France | 31 | 1 |
| Macroeconomic Factors (PEST Analysis) | 31 | 1 |
| Healthcare System in the Country | 32 | 1 |
| Austerity Measures in 2012 | 32 | 1 |
| Total Expenditure on Healthcare as a Percentage of GDP | 33 | 1 |
| Private Expenditure and General Government Expenditure on Healthcare as a Percentage of Total Healthcare Expenditure | 34 | 1 |
| Drug Pricing and Reimbursement Authorities | 35 | 1 |
| Trends in Pricing and Reimbursement | 36 | 1 |
| Drug Price Cuts Affecting Profitability of Parallel Importers | 36 | 1 |
| Economic Committee for Healthcare Products to Change Pricing of Drugs | 36 | 1 |
| Economic Committee for Healthcare Products Imposed Reference Prices on Antihypertensives from 2011 | 36 | 1 |
| Reimbursement Cuts for Drugs with Moderate Clinical Benefit and an End to Reimbursement of Drugs that Offer Minimal Clinical Benefit | 36 | 1 |
| Germany | 37 | 1 |
| Macroeconomic Factors (PEST Analysis) | 37 | 1 |
| Healthcare System in the Country | 38 | 1 |
| Total Expenditure on Healthcare as a Percentage of GDP | 39 | 1 |
| Private and Government Expenditure on Healthcare as a Percentage of Total Healthcare Expenditure | 40 | 1 |
| Drug Pricing and Reimbursement Authorities | 41 | 1 |
| Trends in Pricing and Reimbursement | 41 | 1 |
| Discounts in Branded Products to Reduce the Pharmaceutical Expenditure of Insurance Agencies | 41 | 1 |
| Act on the Reform of the Market for Medicinal Products Prevents Pharmaceutical Players from Fixing Drug Prices | 41 | 1 |
| Expansion of the Reference Pricing System | 41 | 1 |
| Health Insurance Funds to Have Rebate Contracts with Manufacturers of Generics | 42 | 1 |
| Reimbursement Prices in Germany | 42 | 1 |
| Spain | 42 | 1 |
| Macroeconomic Factors (PEST Analysis) | 42 | 1 |
| Healthcare System in the Country | 43 | 1 |
| Total Expenditure on Healthcare as a Percentage of GDP | 43 | 1 |
| Private and Government Expenditure on Healthcare as a Percentage of Total Healthcare Expenditure | 44 | 1 |
| Drug Pricing and Reimbursement Authorities | 45 | 1 |
| Trends in Pricing and Reimbursement | 45 | 1 |
| Spain s Austerity Measures are a Major Blow to the Pharmaceutical Industry | 45 | 1 |
| Increased Price Reduction to be Imposed on Drugs That have been Marketed for More Than 10 Years | 45 | 1 |
| Strong Protests from Patients and Patient Communities | 46 | 1 |
| Prescription of Generics Rather than Branded Products Wherever Possible | 46 | 1 |
| Italy | 46 | 1 |
| Macroeconomic Factors (PEST Analysis) | 46 | 1 |
| Healthcare System in the Country | 47 | 1 |
| Total Expenditure on Healthcare as a percentage of GDP | 47 | 1 |
| Private and Government Expenditure on Healthcare as a Percentage of Total Healthcare Expenditure | 48 | 1 |
| Drug Pricing and Reimbursement Authorities and Procedures | 49 | 1 |
| Trends in Pricing and Reimbursement | 49 | 1 |
| Decision to Lower the Prices of Generics will Result in Substantial Savings for the Government | 49 | 1 |
| Margins of the Wholesalers Cut by 3.6% | 49 | 1 |
| Italian Medicines Agency Publishes List of Important Drugs | 50 | 1 |
| Pharmaceutical Pricing and Reimbursement Asia-Pacific | 51 | 8 |
| China | 51 | 1 |
| Macroeconomic Factors (PEST Analysis) | 51 | 1 |
| Healthcare System in China | 51 | 1 |
| Total Expenditure on Healthcare as a Percentage of GDP | 52 | 1 |
| Private and Government Expenditure on Healthcare as a Percentage of Total Healthcare Expenditure | 53 | 1 |
| Pricing and Reimbursement Approval Process | 54 | 1 |
| Pricing Approval Process | 54 | 1 |
| Reimbursement Process | 54 | 1 |
| Japan | 55 | 1 |
| Macroeconomic Factors (PEST Analysis) | 55 | 1 |
| Healthcare System in the Country | 55 | 1 |
| Total Expenditure on Healthcare as a Percentage of GDP | 56 | 1 |
| Private and Government Expenditure on Healthcare as a Percentage of Total Healthcare Expenditure | 57 | 1 |
| Revisions to the National Health Insurance Drug Price List | 58 | 1 |
| Trends in Pricing and Reimbursement | 58 | 1 |
| Pharmaceutical Pricing and Reimbursement Australia | 59 | 5 |
| Macroeconomic Factors (PEST Analysis) | 59 | 1 |
| Healthcare System in the Country | 60 | 1 |
| Expenditure on Healthcare as a Percentage of GDP | 60 | 1 |
| Private and Government Expenditure on Healthcare as a Percentage of Total Healthcare Expenditure | 61 | 1 |
| Flow Chart for Flow of Funds in Australia | 62 | 1 |
| Trends in Pricing and Reimbursement | 62 | 1 |
| Remuneration Issues of Section 94 Private Hospitals | 62 | 1 |
| Pharmacy Mark-Up Charts | 63 | 1 |
| Pharmaceutical Pricing and Reimbursement Appendix | 64 | 5 |
| Market Definitions | 64 | 1 |
| Abbreviations | 64 | 1 |
| Bibliography | 65 | 2 |
| Research Methodology | 67 | 1 |
| Healthcare System | 67 | 1 |
| Pricing and Reimbursement Process | 67 | 1 |
| Key Trends | 67 | 1 |
| Contact Us | 68 | 1 |
| Disclaimer | 68 | 1 |
